| abstract |
The present invention is represented by the formula (I)n n n n n n n n [Wherein, W is W A -A 1 -W B- (W A is an aryl group which may have a substituent, A 1 is -NR 1- , a single bond, -C (O)-, etc., W B is a substituent) Arylene group, etc.), R is a single bond, -NH-, -OCH 2- , alkenylene group, etc., X is -C (O)-, -CH 2 -etc., M is following Formula (iii) Etc :n n n n n n n n (R 11 , R 12 and R 13 are each independently a hydrogen atom, a hydroxyl group, an amino group, a halogen atom, etc., R 14 is a hydrogen atom or a lower alkyl group, Y is -CH 2 -O- and Z may have a substituent. an arylene group such as, a 2 relates to a medicament containing the compound or its salt and it is represented by a single bond, etc., R 10 is hydroxyl group or lower alkoxy group)].n n n This compound or its salt selectively inhibits the binding of cell adhesion molecules to VLA-4 and has high oral absorption, and prevents and / or prevents inflammatory diseases, autoimmune diseases, cancer metastasis, bronchial asthma, nasal lungs, diabetes, and the like. It is useful as a therapeutic drug.n n n Cell adhesion molecule, VLA-4 |